News
Vicore begins vital endothelial dysfunction study
Vicore Pharma has announced that the first patient has been dosed with its C21 candidate during a pivotal clinical study of endothelial dysfunction.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Vicore Pharma has announced that the first patient has been dosed with its C21 candidate during a pivotal clinical study of endothelial dysfunction.